Vanguard Group
LPCN icon

Vanguard Group’s Lipocine LPCN Stock Holding History

Vanguard Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.78M Hold
221,867
– – ﹤0.01% 3597
2025
Q3 		$635K Sell
221,867
-3,009
-1% -$9.14K ﹤0.01% 3896
2025
Q2 		$711K Sell
224,876
-1,400
-0.6% -$4.54K ﹤0.01% 3842
2025
Q1 		$720K Buy
226,276
+4,817
+2% +$18.7K ﹤0.01% 3799
2024
Q4 		$1.08M Hold
221,459
– – ﹤0.01% 3740
2024
Q3 		$994K Hold
221,459
– – ﹤0.01% 3777
2024
Q2 		$1.82M Hold
221,459
– – ﹤0.01% 3590
2024
Q1 		$1.15M Hold
221,459
– – ﹤0.01% 3763
2023
Q4 		$618K Hold
221,459
– – ﹤0.01% 3973
2023
Q3 		$660K Hold
221,459
– – ﹤0.01% 3977
2023
Q2 		$1.12M Sell
221,459
-2,029
-0.9% -$9.55K ﹤0.01% 3866
2023
Q1 		$1.21M Hold
223,488
– – ﹤0.01% 3858
2022
Q4 		$1.51M Buy
223,488
+118
+0.1% +$860 ﹤0.01% 3772
2022
Q3 		$1.71M Hold
223,370
– – ﹤0.01% 3807
2022
Q2 		$3.04M Hold
223,370
– – ﹤0.01% 3623
2022
Q1 		$5.2M Sell
223,370
-746
-0.3% -$15.6K ﹤0.01% 3508
2021
Q4 		$3.78M Sell
224,116
-316
-0.1% -$5.87K ﹤0.01% 3769
2021
Q3 		$4.16M Hold
224,432
– – ﹤0.01% 3774
2021
Q2 		$5.34M Buy
224,432
+13,576
+6% +$319K ﹤0.01% 3562
2021
Q1 		$5.41M Sell
210,856
-380
-0.2% -$11K ﹤0.01% 3488
2020
Q4 		$4.88M Buy
211,236
+37,243
+21% +$896K ﹤0.01% 3369
2020
Q3 		$4.17M Buy
173,993
+109,034
+168% +$2.9M ﹤0.01% 3240
2020
Q2 		$1.39M Buy
64,959
+2,229
+4% +$28.9K ﹤0.01% 3532
2020
Q1 		$511K Buy
62,730
+8,746
+16% +$69.2K ﹤0.01% 3669
2019
Q4 		$353K Buy
53,984
+12,171
+29% +$312K ﹤0.01% 3859
2019
Q3 		$2M Buy
41,813
+9,115
+28% +$366K ﹤0.01% 3452
2019
Q2 		$1.08M Buy
32,698
+4,426
+16% +$137K ﹤0.01% 3650
2019
Q1 		$1.11M Buy
28,272
+12,025
+74% +$369K ﹤0.01% 3599
2018
Q4 		$359K Sell
16,247
-27,752
-63% -$644K ﹤0.01% 3796
2018
Q3 		$1.03M Buy
43,999
+2,059
+5% +$50.6K ﹤0.01% 3710
2018
Q2 		$927K Sell
41,940
-98
-0.2% -$2.34K ﹤0.01% 3708
2018
Q1 		$1.09M Buy
42,038
+2,777
+7% +$77.3K ﹤0.01% 3630
2017
Q4 		$2.3M Buy
39,261
+71
+0.2% +$4.42K ﹤0.01% 3383
2017
Q3 		$2.65M Buy
39,190
+7,071
+22% +$511K ﹤0.01% 3321
2017
Q2 		$2.19M Buy
32,119
+9,124
+40% +$595K ﹤0.01% 3348
2017
Q1 		$1.52M Buy
22,995
+889
+4% +$57.6K ﹤0.01% 3465
2016
Q4 		$1.38M Sell
22,106
-13,639
-38% -$863K ﹤0.01% 3479
2016
Q3 		$2.71M Buy
35,745
+4,181
+13% +$259K ﹤0.01% 3278
2016
Q2 		$1.63M Buy
31,564
+3,894
+14% +$603K ﹤0.01% 3443
2016
Q1 		$4.77M Buy
27,670
+3,219
+13% +$549K ﹤0.01% 2978
2015
Q4 		$5.38M Buy
24,451
+1,439
+6% +$302K ﹤0.01% 2959
2015
Q3 		$4.63M Buy
23,012
+5,602
+32% +$1.3M ﹤0.01% 3004
2015
Q2 		$2.54M Buy
17,410
+11,071
+175% +$1.37M ﹤0.01% 3320
2015
Q1 		$744K Buy
6,339
+1,255
+25% +$136K ﹤0.01% 3709
2014
Q4 		$455K Buy
5,084
+1,954
+62% +$165K ﹤0.01% 3761
2014
Q3 		$325K Buy
+3,130
New +$389K ﹤0.01% 3816

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's LPCN Position: Q4 2025 in Review

Vanguard Group held its Lipocine (LPCN) position steady in Q4 2025 at 221,867 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3597.

Vanguard Group first reported a position in LPCN in Q3 2014 and has held it in 46 quarters since. The position peaked at $5.41M in Q1 2021. 26 funds tracked by Wall St. Rank hold LPCN as of Q4 2025.

  • Vanguard Group held 221,867 shares of Lipocine worth $1.78M as of Q4 2025.
  • Vanguard Group left its Lipocine share count unchanged in Q4 2025.
  • Lipocine made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3597 holding.
  • Vanguard Group first reported a position in Lipocine in Q3 2014 and has held it in 46 quarters since.
  • Vanguard Group's Lipocine position peaked at $5.41M in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Lipocine as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.